前沿生物（688221）：公司信息更新报告：两款siRNA管线独家授权GSK，携手推进全球合作

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4] Core Insights - The company has entered into an exclusive licensing agreement with GSK for two siRNA pipeline products, which will enhance its global collaboration efforts [4][5] - The revenue forecast for the company is maintained at 143 million, 169 million, and 201 million yuan for 2025, 2026, and 2027 respectively, while the net profit estimates have been revised downwards to -257 million, -208 million, and -199 million yuan for the same years [4][5] - The current stock price corresponds to a price-to-sales (P/S) ratio of 59.3, 50.2, and 42.1 for the years 2025, 2026, and 2027 respectively [4][5] Financial Summary - The company reported a revenue of 114 million yuan in 2023, with a year-over-year growth of 34.8%, and is projected to grow to 201 million yuan by 2027 [8] - The net profit for 2023 was -329 million yuan, with an expected improvement to -199 million yuan by 2027 [8] - The gross margin is expected to improve from 29.0% in 2023 to 34.2% in 2027 [8] - The company’s P/B ratio is projected to increase from 6.3 in 2023 to 17.8 in 2027 [8]